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Risk Statement
Given that terrestrial medical practices must be used as the 
basis for drug choice and use on missions, there is a 
possibility that medications used will be ineffective or 
inappropriate for the actual circumstances encountered on 
missions. 
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Risk Context
Because the human body undergoes a variety of physiological changes 
during spaceflight, there is a risk that terrestrial medications may not perform 
as expected when used during spaceflight. 
Alterations in physiology due to spaceflight could result in unexpected drug 
action on the body (pharmacodynamics) or in unusual drug absorption, 
distribution, metabolism or excretion (pharmacokinetics). 
The spaceflight environment may also have direct effects on stored drugs 
themselves, leading to premature inactivation or degradation of stored drugs. 
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Research Plan  - the approach
Determine 
what 
research 
projects are 
required 
Collect relevant data 
from existing 
terrestrial sources-
medical literature 
(Evidence Book)  
FDA, pharmaceutical 
companies
Synthesize with what 
NASA has learned 
from previous 
spaceflight experience
Indentify effective and feasible research projects
Work with Operations 
– MedOps, ExMC, 
ISSMP
Work with other 
Researchers –
Space Medicine, 
HHC, external 
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Pharmacology  SRP Suggestions:
“Prioritization of Pharmacology-Risk Activities:
Based on available evidence, pharmacology research activities in the near 
future should be prioritized towards the following endeavors:
1. Evaluation of Pharmacokinetics/Pharmacodynamics (PK/PD) of 
antibacterials/antivirals;
2. Assessment of long-term spaceflight on drug distribution including in-vivo
drug metabolism and renal drug clearance;
3. Risk assessment of promethazine-induced QTc prolongation;
4. Testing of shelf-life/potentially protective packaging of prototypical 
medications (e.g., L-thyroxine) in ground-based studies.”
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Revisions from IRP Rev B to Rev C  were intentionally kept to a minimum, 
because of the comprehensive  IRP-wide Gap re-write scheduled for later 
in 2011.  One redundancy in the set of Pharmacology Gaps was corrected.  
Two similar Gaps across Disciplines were merged. 
 Removed Gap PH11; Redundant with Gap PH 2
• Deleted: PH11: What potential polypharmacy problems exist in current spaceflight 
medical practice?
• Kept: PH02: What drug interactions may adversely affect clinical care? 
 Merged Gaps- Integrated Gap SM25 into PH10 
• Deleted: SM25: What are the multisystem effects of promethazine? (a Sensorimotor
Gap)
• Kept: PH10: What are the performance effects of in-flight drugs on exercise, orthostatic 
tolerance, motor control, cognitive function, or other performance-determining aspects of 
physiology? Can novel multidisciplinary therapeutic approaches be used to enhance 
efficacy and reduce side effects? 
Revisions from IRP Rev B to Rev C
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PH01: Inadequate tracking of medication use, indication, efficacy, and side effects. 
PH02: What drug interactions may adversely affect clinical care? Clinical Pharmacy
PH04: What diagnostic, therapeutic, and laboratory technologies are necessary to predict and 
manage medication side effects, interactions, and toxicity during spaceflight? Hardware
PH06: Can a standard procedure for prospective analyses of drugs to be considered for flight 
and periodic analyses of drugs that are used for flight be developed?  Space Medicine
PH07: What are the effects of spaceflight on pharmacokinetics and pharmacodynamics? 
PH09: What is the stability of drugs during long duration spaceflight? 
PH10: What are the effects of in-flight drugs on exercise, orthostatic tolerance, motor control, 
cognitive function, or other performance-determining aspects of physiology? Can novel 
multidisciplinary therapeutic approaches be used to enhance efficacy and reduce side 
effects? 
PH13: Which sleep aid is best in flight in terms of efficacy? In terms of limited side effects? 
BHP
PH15: Are the antimicrobials carried on board effective against microbes that exhibit 
spaceflight-related changes? 
Gaps
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PH01: Inadequate tracking of medication use, indication, efficacy, and side effects. 
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Proposals are solicited by NASA in the areas of: 
Visual Acuity and Ocular Structure and Function; Fluid Distribution; Team Social, 
Technical, and Task Roles; and Effects of Constrained, Asynchronous 
Communication on Operational Tasks. 
In addition, NASA is requesting short-term investigations (< 1yr and < $100K) that provide 
innovative approaches to any of the defined risks contained in the Integrated 
Research Plan (IRP) of the Human Research Program.
The NSBRI portion of this NRA solicits for:
Microgravity-Induced Visual Alterations and Intracranial Pressure, Cardiovascular 
Alterations, Human Factors and Performance Musculoskeletal Alterations, 
Neurobehavioral and Psychosocial Factors, Sensorimotor Adaptation, Smart Medical 
Systems and Technology
NASA Research Announcement  8/2011
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Research Plan Top Priorities
(in order of importance and urgency)
1. Improve information about inflight medication efficacy and side effects
2. Improve knowledge of drug stability during spaceflight
3. Prepare for virulence changes in space
4. Develop a better understand of spaceflight effects on metabolism and radiation-
induced oxidative damage
5. Gather basic PK information to better inform dosing
6. Investigate therapies for SMS
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Research Plan Top Priorities
(in order of importance and urgency)
1. Improve information about inflight medication efficacy and side effects Collect 
data on current inflight medication use efficacy and side effects. Collect existing data 
from NASA data archives. 
2. Improve knowledge of drug stability during spaceflight discussions in progress 
with ExMC and Radiation; in process of negotiating data sharing arrangements with 
FDA and pharmaceutical companies
3. Prepare for virulence changes in space: Determine the efficacy of antibiotics and 
antifungals in ground analog. 
4. Develop a better understand of spaceflight effects on metabolism and 
radiation-induced oxidative damage
5. Gather basic PK information to better inform dosing: Measure expression of 
genes involved in drug metabolism by the liver. 
6. Investigate therapies for SMS: Develop alternative therapeutic possibilities. 
Directly addresses: 
PH01 Inadequate tracking of medication use, indication, and side effects. 
Medication Symptom Tracking Questionnaire - collect research information about 
inflight drug use going forward (proposal submitted 9/2011)
Limitation - requires voluntary crew participation, most flight surgeons feel collection of 
research information is unnecessary and burdensome on crew
Data Mining from LSDA/LSAH, ExMC, BHP, NSBRI, FDA 
Limitations- data are sparse; there is no indication of medication efficacy; access to NASA data 
sets is very limited, intensive data analysis requires significant personnel time
Will also inform all other PH Gaps, particularly:
PH10 What are the effects of in-flight drugs on exercise, orthostatic tolerance, motor control, cognitive 
function or other performance-determining aspects of physiology? 
Deliverables: Hard data about medication use frequency as well as  identification and frequency of 
untoward effects; will inform Gaps in other Disciplines, Space Medicine, BHP,  ExMC. 
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2. Improve knowledge of drug stability during spaceflight
3. Prepare for virulence changes in space: Determine the efficacy of antibiotics and 
antifungals in ground analog. 
4. Develop a better understand of spaceflight effects on metabolism and 
radiation-induced oxidative damage
5. Gather basic PK information to better inform dosing: Measure expression of 
genes involved in drug metabolism by the liver. 
6. Investigate therapies for SMS: Develop alternative therapeutic possibilities. 
Research Plan Top Priorities
(in order of importance and urgency)
1. Conducting in-house data mining to collect and analyze unpublished data from 
previous spaceflight analog and spaceflight experiments. 
2. In process of negotiating data sharing rran em nts with FDA and pharmaceutical 
comp nies to get as much information as possible from existing terrestrial sources. 
3. Arr nging  pilot study with he FDA stability labs, in which th y will conduct a 
comprehensi  batte y of t sts of some return d flight medications.  
Directly addresses: 
PH09 What is the stability of drugs during long duration spaceflight? 
Also addresses specific SRP concerns. 
Deliverables: Information will be used to determine future research needs for long 
duration mission planning. 
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Research Plan Top Priorities
(in order of importance and urgency)
3. Prepare for virulence changes in space: Determine the efficacy of antibiotics and 
antifungals in ground analog. 
Proposal submitted 9/2011, in conjunction with JSC Microbiology (Mark Ott SF/NASA)
3 microorganisms found on the ISS 
(Psueodomonas, Staph aureus, Salmonella enterica serovar Typhimurium)
grown in a culture system that mimics microgravity
measuring mean inhibitory concentration of 2 medications used to combat infections by each 
organism 
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Research Plan Top Priorities
(in order of importance and urgency)
3. Prepare for virulence changes in space: Determine the efficacy of antibiotics and 
antifungals in ground analog. 
4. Develop a better understand of spaceflight effects on metabolism and 
radiation-induced oxidative damage
5. Gather basic PK information to better inform dosing: Measure expression of 
genes involved in drug metabolism by the liver. 
6. Investigate therapies for SMS: Develop alternative therapeutic possibilities. 
Limitations: Omnibus Proposal is limited to 1 yr and $100K; microbial changes could be transient, 
requiring a faster protocol than typically used for MIC experiment; different microorganisms may 
not behave the same way in the model system.  
Directly addresses: 
PH15 Are the antimicrobials agents carried on board effective against microbes that exhibit spaceflight-
related changes?
Also addresses specific SRP concerns. 
Deliverables: Will deliver pilot information that will help determine the scope of any potential problem, 
develop methods and validate the rotating culture system for pharmaceutical testing, and provide a 
framework for more comprehensive studies in the future.  Information regarding antimicrobial efficacy 
(including required dosages) would ultimately inform Space Medicine’s treatment decisions. 
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Research Plan Top Priorities
(in order of importance and urgency)
5. Gather basic PK information to better inform dosing:
Pilot Study - Liver function in mice after radiation exposure 
A specimen-sharing  add-on study 
Groups of 6 mice were exposed to 50 mGy, or 6 Gy, or 50 mGy followed by 6 Gy. RNA was 
extracted from liver samples. 
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Research Plan Top Priorities
(in order of importance and urgency)
5. Gather basic PK information to better inform dosing:
Pilot Study - Liver function in mice after radiation exposure 
Limitations: mice are not humans; single high dose exposures may cause different effects than 
chronic low dose exposure;  because this was an add-on to someone else's study, no drug 
administration was possible; radiation alone may not adequately reproduce the spaceflight 
environment; changes at the RNA level may not reflect activity at the protein level. 
Directly addresses: 
PH7 What are the effects of spaceflight on pharmacokinetics and pharmacodynamics?
Also addresses specific SRP concerns. 
Deliverables: Radiation exposures can alter expression of genes involved in metabolism of 
administered medications. The same radiation exposures also alter express of gene involved in redox
homeostasis. 
Page No. 17 SRP 2011 SK3/Wotring/3-6332
Research Plan Top Priorities
(in order of importance and urgency)
4. Develop a better understand of spaceflight effects on metabolism and 
radiation-induced oxidative damage
5. Gather basic PK information to better inform dosing: Measure expression of 
genes involved in drug metabolism by the liver. 
6. Investigate therapies for SMS: Develop alternative therapeutic possibilities. 
Ground based animal study in progress: Pilot Studies of Radiation Damage in Organ 
Tissues of Mice (previous 2 slides)
Flight animal study in progress - Effect of Spaceflight on Expression of Metabolic Enzyme 
Genes in Mice
permitted access to livers from mice who experienced a shuttle flight (through the 
Biological Specimen Sharing Program)
will perform gene expression studies similar to the Radiation Damage study just 
described, as well as protein analyses
Limitations: mice are not humans; exhaustive tissue sharing arrangements increased the 
length of time between animal sacrifice and liver dissection – tissue quality may be somewhat 
compromised; an add-on study so no drugs could be administered
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Research Plan Top Priorities
(in order of importance and urgency)
4. Develop a better understand of spaceflight effects on 
metabolism and radiation-induced oxidative damage
Directly addresses:
PH7 What are the effects of spaceflight on 
pharmacokinetics and pharmacodynamics?
Also addresses specific SRP concerns. 
Deliverables: Information regarding the effects of 
spaceflight on liver gene and protein expression, 
which will narrow the focus for future research. 
Study in progress - Effect of 
Spaceflight on Expression of 
Metabolic Enzyme Genes in Mice
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Research Plan Top Priorities
(in order of importance and urgency)
4. Develop a better understand of spaceflight effects on metabolism and 
radiation-induced oxidative damage
Ground based radiation+oxidatative stress proposal submitted - Effects Of Radiation And 
Dietary Iron On Expression Of Genes And Proteins Involved In Drug Metabolism – proposal 
submitted 9/2011
Another study from the Nutritional Biochemistry Discipline used rats with a 3 Gy radiation dose 
delivered in several session over 3 weeks. Some animals were given a high iron diet. 
will perform gene and protein expression studies similar to the flight study just described
Limitations: rodents are not humans;  because this was an add-on to someone else's study, 
no drug administration was possible
Directly addresses:
PH7 What are the effects of spaceflight on pharmacokinetics and pharmacodynamics?
Also addresses specific SRP concerns. 
Deliverables: Information regarding the effects of spaceflight on liver gene and protein 
expression, which will narrow the focus for future research. Validation of rat model with lower, 
fractionated dose radiation exposure. 
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Research Plan Top Priorities
(in order of importance and urgency)
6. Investigate therapies for SMS:
Funded proposal –
Effect of Anti-Motion Sickness Medication Combinations on QTc Interval 
Limitations: Will take considerable time to have 50 subjects complete this study; 
this study does not include any efficacy measures.
Directly addresses: 
PH10 What are the effects of in-flight drugs on exercise, orthostatic tolerance, motor 
control, cognitive function, or other performance-determining aspects of physiology? Can 
novel multidisciplinary therapeutic approaches be used to enhance efficacy and reduce 
side effects?
Also addresses specific SRP concerns regarding the potential for cardiac side effects with 
promethazine. 
Deliverable: Measurements of cardiac activity collected during SMS treatments; an 
indicator of medication safety. Depending on result, could provide evidence for 
replacement of certain medications or for use of one medication combination over another. 
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Research Plan Top Priorities
(in order of importance and urgency)
6. Investigate therapies for SMS:
Funded project –
Effect of Anti-Motion Sickness Medication Combinations on QTc Interval 
Virginia Wotring, JSC SK/USRA, James P. Locke, JSC/SD and Todd T. Schlegel, JSC/SK
to compare the safety of two new combination medication treatments for motion sickness 
with  1) other medication treatments already in use and 2) an inactive (placebo) control. 
will compare the effect on QTc, R-R and other measures derived from high resolution 12-
lead ECGs. 
each of the 50 subjects will participate in 5 separate sessions, with each session involving 
the ingestion of a different combination of medicines (or placebo) plus the performance of 
an ECG and side effect questionnaire before medication, 90 minutes after medication 
administration, and 24 hours after. 
1) scopolamine/modafinil/ondansetron 
2) promethazine/modafinil/ondansetron 
3) scopolamine/dextroamphetamine
4) promethazine/dextroamphetamine
5) placebo
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Back Up Slides
Page No. 23 SRP 2011 SK3/Wotring/3-6332
Contributing Factors 
(Master Logic Diagram – MLD – new version)
Some confusion was expressed 
regarding the connection of the 3 main 
elements. We have revised the diagram 
to emphasize that pharmacokinetics and 
unique aspects of spaceflight both affect 
pharmacodynamics, mostly in terms of  
circulating concentration of active 
compounds.  
All three of these top 
level elements are 
linked. They affect one 
another, and they 
affect physiology. 
Validation of 
medication stability 
and therapeutic 
efficacy 
(3a)
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Drugs are metabolized by enzymes, which 
are proteins. 
remember that     DNA     → RNA     → protein
Protein functionProtein expressionGene expression
Enzyme assay –
requires unique assay 
for every enzyme
which means that experiments can probe RNA expression levels or protein expression/function 
Western blot–
requires unique 
antibody for every 
protein
PCR– can examine 96 
mRNAs simultaneously
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Livers were removed from the
anesthetized animals immediately after
sacrifice, and the livers flash-frozen in
liquid nitrogen. Tissue will homogenized,
RNA extracted, and purified. Quality of
RNA samples will be evaluated with the
Agilent system in the HACD Core Lab.
Complementary DNA will be prepared
from the RNA samples, and used to run
commercially available RT-PCR
screening arrays for DNA Repair and
Drug Metabolism (SuperArray,
SABiosciences, Qiagen). Use of these
large pre-optimized primer sets for this
pilot experiment will allow efficient
screening of over 150 gene products
using the BioRad Cfx96 Real-time PCR
System in the HACD Core Lab. The
results from this phase of the experiment
should allow us to not only determine if
radiation exposure affects expression
level of genes coding for these enzymes,
but also to determine if particular groups
of enzymes are affected more than
others. For example, we might see
enzymes that repair breaks in double-
stranded DNA upregulated by radiation
exposure, while those that repair DNA
mismatches or transport drugs across
membranes are relatively unaffected,
allowing us to focus future research
effects to the most important targets.
Extract RNA from tissue
Verify quantity and quality 
of RNA
Make cDNA to use as 
template for PCR 
Perform PCR using primers 
coding for genes of interest 
and reference genes
Calculate gene expression 
relative to reference genes
4 hour experiment - lab 
analysis complete & 
statistical analysis 
underway
24 hour experiment  - RNA 
extractions complete 
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Ct shifts allow quantitation of 
expression levels relative to reference 
genes
Mouse that was exposed to both 
radiation treatments 
Control animal
Cyp17a1 Cyp17a1
Cyp19a1Cyp19a
This Ct shift means a 7-fold increase in expression of this gene.   
GapdhGapdh
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Low High Both Unchanged
Drug Metabolism Genes 5 7 7 74
(Changes up to 240 fold)
DNA  Repair Genes 6 14 4 77
(No changes over 3-fold)
Number of genes changed:
Unchanged genes can be safely eliminated from future, more detailed investigations at the protein 
level. 
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Data are normalized gene expression relative to a set of reference genes  (ActB, Hprt1, Gstm1, Gad1, Gapdh); deviations 
from the dotted line at y=1 indicate changes from gene expression measured in control animals. The data shown here are 
those whose gene expression changed by > 1.5 fold with p < 0.05 (compared to control; indicated by *) in at least one of the 
treatment groups (low, high or both).  Data from 74 genes with no significant expression changes are not shown. Detailed 
analysis (including SEM and statistical analysis) is underway. 
No change
Drug & lipid Steroid Antioxidants (& lipid metabolism) Glycolysis
Metabolism Array Preliminary Results 
*
*
*
*
*
*
* *
*
**
*
*
*
*
***
* *
*
* *
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Data are normalized gene expression relative to a set of reference genes (Rfc1, Ccnh, Atxn3, Actb); deviations from the 
dotted line at y=1 indicate changes from gene expression measured in control animals.  The data shown here are those 
whose gene expression changed by > 1.5 fold with p < 0.05 (compared to control; indicated by *) in at least one of the 
treatment groups (low, high or both).  Data from 77 genes with no significant expression changes are not shown. Detailed 
analysis (including SEM and statistical analysis) is underway. 
DNA handling & 
packaging
Proofreading & damage sensing proteins
DNA mutation and damage repair enzymes Proofreading & 
damage-sensing
No change
*
*
*
*
**
**
*
*
*
**
* *
*
*
**
*
*
*
DNA Repair Array Preliminary Results 
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Clinical  liver function tests from serum
All measured values from liver function tests alkaline phosphatase (ALP), aspartate 
transaminase (AST), and alanine transaminase (ALT) are within normal ranges, although there 
some are significant differences from controls (indicated by *). The 4 hour experiment is the left 
group of columns on each graph; the 24 hour experiment is on the right. N=6 for all, except 
where noted  
*
*
*
*
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Drug Metabolism Results
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Drug Metabolism Results
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DNA Repair Results
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DNA Repair Results
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DNA Repair Results
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DNA Repair Results
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Drug Metabolism Gene Relationships
    Down-regulation 
    Up-regulation 
    Regulation Direction Unknown 
    Coexpression 
    Chemical Modification 
    Physical Interaction 
      Predicted Protein Interaction 
      Predicted TFactor Regulation 
    Other 
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DNA Repair Gene Relationships
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    Other 
